USE OF A SPIRONOLACTONE-BASED COMPOSITION THAT EXHIBITS AN INHIBITORY ACTION ON T-LYMPOCYTE ACTIVATION WHICH IS USEFUL FOR PREVENTING AND/OR TREATING MULTIPLE SCLEROSIS
World Intellectual Property Organization Patent
Stats
Importance
Abstract
The present invention relates to the use of spironolactone for the preparation of a pharmaceutical composition intended for preventing and/or treating multiple sclerosis. Furthermore, the invention relates to the use of spironolactone directly in T-lymphocytes or dendritic cells obtained from a blood sample taken from the patient and then injected back into the circulation. Therefore, the present invention relates to the use of a composition that comprises spironolactone that can be used in the treatment of multiple sclerosis, which covers the administration of spironolactone directly or of lymphocytes pre-treated with spironolactone, or dendritic cells to individuals requiring such treatment. Spironolactone is an orally administered drug that is less expensive than many of the treatments available for MS and, furthermore, has the advantage of being a known compound already used in humans over extended periods and therefore the adverse effects thereof have been described in clinical studies.
First Claim
Family
International Classification(s)
Cited Art Landscape
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address